Home
About
Overview
Sharing Data
ORCID
Help
History (38)
Consensus building for development of outpatient adverse drug event triggers.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Organizational Policy
Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Head tremor secondary to MS resolved with rituximab.
See All 38 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Head tremor secondary to MS resolved with rituximab.
Chansakul C, Moguel-Cobos G, Bomprezzi R. Head tremor secondary to MS resolved with rituximab. Neurol Sci. 2011 Dec; 32(6):1157-60.
View in:
PubMed
subject areas
Adult
Antibodies, Monoclonal, Murine-Derived
Brain
Female
Head
Humans
Immunologic Factors
Injections, Intravenous
Magnetic Resonance Imaging
Multiple Sclerosis
Rituximab
Tremor
authors with profiles
Roberto Bomprezzi MD, PhD